腫瘤

iNKT細胞減少與急性髓性白血病生存差有關

作者:Najera Chuc AE等 來源:Journal of Cancer Research & Clinical Oncology 日期:2012-06-21
導讀

         iNKT細胞減少與急性髓性白血病生存差有關

Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia 

iNKT細胞減少與急性髓性白血病生存差有關

Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia

Background T lymphocytes play an important role in the immunosurveillance of patients with hematologic malignancies. No study has so far examined the association between the number of lymphocyte subsets at diagnosis and overall survival (OS). We examined this relationship in adult patients with de novo acute myeloid leukemia (AML).       

Methods A longitudinal prospective study was conducted on 28 AML patients. Peripheral blood (PB) and bone marrow (BM) were obtained before chemotherapy to quantify the number of CD4+ and CD8+ T cells, natural killer (NK), invariant NKT (iNKT), and type-1 and type-2 dendritic cells. The Kaplan–Meier and Cox proportional hazard model were used to determine significant association between the number of each cell subtype and survival.       

Results BM counts of CD4+ lymphocytes >506.11/μL and CD8+ T lymphocytes >556.02/μL and a PB count of iNKT cells <0.2/μL were associated with poor OS by univariate analysis (P = 0.015, P = 0.009, P = 0.033 respectively). Multivariate analysis showed that an iNKT count <0.2 cells/μL is an independent prognostic factor for OS.       

Conclusion An iNKT cell number of <0.2/μL confers a poor prognosis in de novo AML patients.

原文鏈接:http://www.springerlink.com/content/a146937670t78771/

 

分享:

相關文章

評論

我要跟帖
發表
回複 小鴨梨
發表

copyright©醫學論壇網 版權所有,未經許可不得複製、轉載或鏡像

京ICP證120392號  京公網安備110105007198  京ICP備10215607號-1  (京)網藥械信息備字(2022)第00160號
//站內統計 //百度統計 //穀歌統計 //站長統計
*我要反饋: 姓    名: 郵    箱: